The International Generic and Biosimilar Medicines Association (IGBA) recently sent a letter to HHS Secretary Alex Azar applauding the administration’s ongoing efforts to lower drug prices—as well as the FDA’s prioritization of improving the efficiency of biosimilar and interchangeable product development—and asking for a key change to the biosimilar approval process.
The International Generic and Biosimilar Medicines Association (IGBA) recently sent a letter to HHS Secretary Alex Azar applauding the administration’s ongoing efforts to lower drug prices—as well as the FDA’s prioritization of improving the efficiency of biosimilar and interchangeable product development—and asking for a key change to the biosimilar approval process.
Currently, if a biosimilar developer were to use a reference product licensed in a regulatory jurisdiction outside of the United States, the developer would not only need to show that the product was approved under similar scientific and regulatory standards to those held by the FDA, but also supply data from bridging studies to demonstrate the comparability of the US- and non—US-licensed reference products.
Within their letter, the IGBA asks the FDA to waive the requirement for such bridging studies, saying that bridging studies not only add hundreds of thousands to millions of dollars to development costs, but also add no scientific value to the regulatory process. Furthermore, they argue, because these trials are not necessary, they are unethical.
IGBA offered its own solution, stating that the bridge between the US-licensed reference product and the non-US licensed reference can be established without the use of expensive bridging studies, and called on the FDA to develop a concept of a global comparator product that would allow for a waiver of bridging studies.
The comparator would be the reference product used for head-to-head similarity or comparability studies with a biosimilar candidate, and would be authorized in a jurisdiction that has a well-established regulatory framework, experience with evaluation of the biotherapeutic products, and post-marketing surveillance activities. If the product has the same active pharmaceutical ingredient as the US-licensed reference product and was approved on essentially the same original data package as the US-licensed product, and if confidentiality agreements between regulatory agencies that provide a framework for cross-checking product information, then bridging studies could reasonably be waived.
“This constitutes an important and effective development tool in reducing the development costs for biosimilars and interchangeable products, will increase competition and hence improve access to these live-saving treatments,” read the letter.
IGBA stated that it will follow up with both the FDA and the EMA to share an internal mapping of bridging study requirements by regulatory agencies around the world.
In fact, the potential for the FDA to do away with bridging studies is not an entirely novel idea. In an interview in February 2018, FDA Commissioner Scott Gottlieb, MD, said that he was exploring the possibility.
“I have lawyers now looking at this,” said Gottlieb. The FDA had been looking into the issue for a few months and he noted that it may be “…hard for us to get there without legislation, but we’re not done looking at this.”
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.